Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases. Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases. In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials. Nuvamid’s research is built upon the emerging scientific findings linking age-related disease pathologies with NAD metabolism. Nuvamid designed novel NAD metabolism modulators and gathered extensive preclinical data to develop a portfolio of drugs targeting immune disorders.
| Website | https://nuvamid.com |
| Employees | 4 (4 on RocketReach) |
| Founded | 2019 |
| Address | Avenue Reverdil 4-6, Nyon, Vaud 1260, CH |
| Phone | +41 21 311 53 52 |
| Industry | Biotechnology |
| Keywords | Rare Disease Treatment, Genetic Diseases, Precision Medicine, Clinical Stage Biotech, Clinical Trials, Innovative Therapies, Pharmaceutical Research, Drug Development, Therapeutic Development, Biotech Innovation, Life Science Research, Biotechnology Research, New Therapeutics, Biopharmaceutical, Drug Discovery, Molecular Therapeutics |
Looking for a particular Nuvamid employee's phone or email?
Nuvamid Questions
Ousmane Cissé is the Chief Medical Officer of Nuvamid.
4 people are employed at Nuvamid.
Nuvamid is based in Nyon, Vaud.
Top Nuvamid Employees
-
Matthias Canault
Scientific Director at Nuvamid
Aix-en-Provence, FR1 -
Cecile Cros
R and D Manager at Nuvamid
Lausanne, VD, CH2 -
1
Related Companies
